Prof. Dr. rer. nat. Michael Hummel

Molecular Diagnostics
Institute of Pathology
Charité - Universitätsmedizin Berlin
Charitéplatz 1
10117 Berlin
Tel: +49 30 450 536 642
E-Mail: michael.hummel(at)charite.de
University Education
- 1985 Diploma, Institute of Biology, University Cologne
Professional Experience (selection)
- 1986-1990 Ph.D. student, Institute of Pathology, FU Berlin
- 1990-1999 Postdoctoral research fellow, Institute of Pathology, FU Berlin
- 1994- Head of the Molecular Pathology Group, Institute of Pathology, Charité
Research Fields
- Main field: Molecular mechanisms in malignant lymphomas
- Current research interest: Epigenetic gene regulation in Hodgkin lymphoma
- Identification of biomarkers for precision oncology
Most important Awards, Grants or Scientific Achievements
- 1986-1988 Berlin Senate (NAFöG)
- 2008- Member, Deutsche Krebsgesellschaft, Abteilung Experimentelle Krebsforschung (AEK) e.V.
- Director of the German Biobank Node/Alliance
- Head of the Central Biobank Charité (ZeBanC)
Selected References
- Akpa, C.A., Kleo, K., Oker, E., Tomaszewski, N., Messerschmidt, C., López, C., Wagener, R., Oehl-Huber, K., Dettmer, K., Schoeler, A., Lenze, D., Oefner, P.J., Beule, D., Siebert, R., Capper, D., Dimitrova, L. & Hummel, M. (2020) "Acquired resistance to DZNep-mediated apoptosis is associated with copy number gains of AHCY in a B-cell lymphoma model." BMC Cancer. 2020;20(1):427.
- Seitz, V., Kleo, K., Dröge, A., Schaper, S., Elezkurtaj, S., Bedjaoui, N., Dimitrova, L., Sommerfeld, A., Berg, E., von der Wall, E., Müller, U., Joosten, M., Lenze, D., Heimesaat, M.M., Baldus, C., Zinser, C., Cieslak, A., Macintyre, E., Stocking, C., Hennig, S. & Hummel, M. (2020) "Evidence for a role of RUNX1 as recombinase cofactor for TCRβ rearrangements and pathological deletions in ETV6-RUNX1 ALL." Sci Rep. 2020;10(1):10024.
- Kleo, K., Dimitrova, L., Oker, E., Tomaszewski, N., Berg, E., Taruttis, F., Engelmann, J.C., Schwarzfischer, P., Reinders, J., Spang, R., Gronwald, W., Oefner, P.J. & Hummel, M. (2019) "Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma." BMC Cancer. 2019;19(1):322.
- Akpa, C.A., Kleo, K., Lenze, D., Oker, E., Dimitrova, L. & Hummel, M. (2019) "DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations." PLoS ONE. 2019;14(8):e0220681.
- Vollbrecht, C., Lehmann, A., Lenze, D. & Hummel, M. (2018) "Validation and comparison of two NGS assays for the detection of EGFR T790M resistance mutation in liquid biopsies of NSCLC patients." Oncotarget. 2018;9(26):18529-18539.